Lonza has extended two ongoing collaborations with unnamed major biopharmaceutical companies. One covers the commercial-scale filling of antibody-drug conjugates (ADCs), the other bioconjugation. Financial details were not disclosed in either case.

As part of the former partnership, Lonza will build a dedicated line at its site in Stein, Switzerland, for the aseptic filling of highly potent ADCs and lyophilisation under containment. The new line is expected to be operational in 2027 and to create about 115 new jobs at peak capacity.